Inlyta savings card: as little as $0 a month with commercial insurance

How to pay the least

Ask for the cash price

Inlyta

We didn’t find one.

Ask your pharmacy for Inlyta’s cash price, and one or two other pharmacies too.
Inlyta’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Pfizer Patient Assistance Program. Meet the income requirements – Your annual household pre-tax income cannot exceed 300% of the Federal Poverty Level, adjusted for household size. Or call 1-844-989-7284.

See if you qualify

Compare every option

Brand nameInlyta

Authorized genericaxitinib

Regular genericaxitinib

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Inlyta?

The original

–

Brand nameThe maker’s card

Pfizer Oncology Together Co-Pay Savings Program

Savings card from Pfizer

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a month

The card takes up to $10,600 a year off your co-pay.

Or call 1-877-744-5675. See the offer on pfizeroncologytogether.com

In the maker’s words

“pay as little as $0 per month for their Pfizer Oncology treatment.”

From the maker’s offer on pfizeroncologytogether.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Inlyta itself, from the same company, sold without the brand name, and usually for less. For now Inlyta is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Advanced kidney cancer (renal cell carcinoma)

What the FDA label says

INLYTA is a kinase inhibitor indicated:

in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC.
as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

Source: the FDA label for Inlyta (U.S. Pharmaceuticals), March 12, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/inlyta/